Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-007 · Monitoring
CV-10: LDL-C above the pathway threshold on treatment
LDL-C above the pathway threshold on treatment. Evaluates lipid-lowering therapy active.
Active rulePriority 3Cardio engine v1.0.0
Condition
- lipid-lowering therapy active
- established ASCVD
- LDL-C ≥ 70 mg/dL (≥ 55 mg/dL for very high risk)
What it reports
- LDL-C is above the 2022 ACC pathway threshold for considering added therapy
Recommended next steps (for physician review)
- Review adherence and tolerability
- Physician to consider added therapy per the pathway
Diagnostic boundary
- Does not name a drug.
Evidence
- EV-ACC-ECDP-2022Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk. J Am Coll Cardiol. 2022;80(14):1366-1418.Supports: LDL-C thresholds of 55 and 70 mg/dL for considering added therapy in ASCVD
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.